{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:11:52Z","timestamp":1778105512728,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017657","name":"Fondation de l'H\u00f4pital G\u00e9n\u00e9ral de Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017657","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014131","name":"McGill University Health Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jaip.2025.12.029","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:43:23Z","timestamp":1767339803000},"page":"1074-1080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Blistering Drug Eruptions: Diagnostic Challenges and Management in Clinical Practice: Unmasking the Cause: A Grand Rounds Review of Blistering Drug Eruption"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-5032","authenticated-orcid":false,"given":"Ana Maria","family":"Copaescu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ardern-Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie K.","family":"Hickerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Seccombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherrie J.","family":"Divito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonny","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.12.029_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: Building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.12.029_bib2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.alit.2025.05.002","article-title":"Updates in the pathogenesis of SJS\/TEN","volume":"74","author":"Justice","year":"2025","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2025.12.029_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.13562","article-title":"EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity","volume":"74","author":"Brockow","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.12.029_bib4","article-title":"Updates in SJS\/TEN: collaboration, innovation, and community","volume":"10","author":"Marks","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2025.12.029_bib5","article-title":"Severe ocular complications of SJS\/TEN and associations among pre-onset, acute, and chronic factors: a report from the international ophthalmology collaborative group","volume":"10","author":"Ueta","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2025.12.029_bib6","article-title":"Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions","volume":"9","author":"Copaescu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2025.12.029_bib7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.12.029_bib8","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1016\/j.jid.2022.05.1059","article-title":"IFN-gamma ELISpot in severe cutaneous adverse reactions to first-line anti-tuberculosis drugs in an HIV endemic setting","volume":"142","author":"Porter","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaip.2025.12.029_bib9","article-title":"Dose dependent antimicrobial cellular cytotoxicity-implications for ex vivo diagnostics","volume":"12","author":"Copaescu","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2025.12.029_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjd.12109","article-title":"In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions","volume":"168","author":"Polak","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.12.029_bib11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaip.2020.08.012","article-title":"Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure","volume":"9","author":"Lehloenya","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.12.029_bib12","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jaip.2025.08.001","article-title":"HLA-B alleles with shared peptide binding specificities define global risk of cotrimoxazole-induced SCAR","volume":"13","author":"Li","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.12.029_bib13","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamadermatol.2024.3575","article-title":"Incidence, in-hospital and long-term mortality, and sequelae of epidermal necrolysis in adults","volume":"160","author":"Bettuzzi","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.12.029_bib14","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamadermatol.2021.3154","article-title":"Assessment of treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis: insights from a pan-European multicenter study","volume":"157","author":"Kridin","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.12.029_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jaad.2014.06.026","article-title":"Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review","volume":"72","author":"Canavan","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.12.029_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.iac.2022.01.005","article-title":"Recognizing drug hypersensitivity in pigmented skin","volume":"42","author":"Lehloenya","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2025.12.029_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12016-017-8667-7","article-title":"Current perspectives on erythema multiforme","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.12.029_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.autrev.2014.01.011","article-title":"Diagnosis and classification of pemphigus and bullous pemphigoid","volume":"13","author":"Kershenovich","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaip.2025.12.029_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13023-019-1089-2","article-title":"Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients","volume":"14","author":"Genovese","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2025.12.029_bib20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamadermatol.2014.4844","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission","volume":"151","author":"Bequignon","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.12.029_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6928363","article-title":"Immunohistopathological findings of severe cutaneous adverse drug reactions","volume":"2017","author":"Orime","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jaip.2025.12.029_bib22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.det.2012.06.008","article-title":"Direct immunofluorescence testing in the diagnosis of immunobullous disease, collagen vascular disease, and vascular injury syndromes","volume":"30","author":"Magro","year":"2012","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaip.2025.12.029_bib23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamadermatol.2023.1693","article-title":"Assessment of need for improved identification of a culprit drug in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"159","author":"Li","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.12.029_bib24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.autrev.2011.04.003","article-title":"Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature","volume":"10","author":"Sagi","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaip.2025.12.029_bib25","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3390\/v16121896","article-title":"Pemphigus and bullous pemphigoid following COVID-19 vaccination: a systematic review","volume":"16","author":"Martora","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.jaip.2025.12.029_bib26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/cup.14687","article-title":"Toxic epidermal necrolysis-like cutaneous toxicity following chimeric antigen receptor T-cell therapy in recurrent large B-cell lymphoma","volume":"51","author":"Bhullar","year":"2024","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaip.2025.12.029_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40257-016-0235-z","article-title":"Paraneoplastic pemphigus and autoimmune blistering diseases associated with neoplasm: characteristics, diagnosis, associated neoplasms, proposed pathogenesis, treatment","volume":"18","author":"Kartan","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2025.12.029_bib28","article-title":"An updated review of the diagnostic methods in delayed drug hypersensitivity","volume":"11","author":"Copaescu","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2025.12.029_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaci.2023.03.024","article-title":"In vitro\/ex vivo assays for severe cutaneous drug reactions","volume":"152","author":"Copaescu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.12.029_bib30","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaip.2020.12.052","article-title":"The role of in vivo and ex vivo diagnostic tools in severe delayed immune-mediated adverse antibiotic drug reactions","volume":"9","author":"Copaescu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.12.029_bib31","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you safely go?","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.12.029_bib32","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.jaip.2024.06.047","article-title":"Delayed skin testing for systemic medications: helpful or not?","volume":"12","author":"Barbaud","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.12.029_bib33","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.12.029_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacig.2021.11.001","article-title":"Blister fluid as a cellular input for ex vivo diagnostics in drug-induced severe cutaneous adverse reactions improves sensitivity and explores immunopathogenesis","volume":"1","author":"Awad","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2025.12.029_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/cpt.2343","article-title":"Immunopharmacogenomics: mechanisms of HLA-associated drug reactions","volume":"110","author":"Deshpande","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2025.12.029_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cpt.890","article-title":"Research directions in genetic predispositions to Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"103","author":"Manolio","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2025.12.029_bib37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2025.12.029_bib38","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2025.12.029_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","article-title":"Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions","volume":"151","author":"Gibson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.12.029_bib40","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/s41592-024-02541-x","article-title":"A new understanding of tissue biology from MS-based proteomics at single-cell resolution","volume":"21","author":"Nordmann","year":"2024","journal-title":"Nat Methods"},{"key":"10.1016\/j.jaip.2025.12.029_bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/vision9030078","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of ophthalmic management and treatment","volume":"9","author":"Sawires","year":"2025","journal-title":"Vision (Basel)"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825012425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825012425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T10:06:47Z","timestamp":1778062007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825012425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2213219825012425"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.12.029","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blistering Drug Eruptions: Diagnostic Challenges and Management in Clinical Practice: Unmasking the Cause: A Grand Rounds Review of Blistering Drug Eruption","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}